Saturday, June 15, 2024

Global Challenge of TB-COVID Co-Infection: An Updated Systematic Review

Similar articles

In a recent systematic review, researchers have delved into the dual health threat posed by tuberculosis (TB) and COVID-19 co-infection, revealing critical insights into its epidemiology, treatment outcomes, and fatality rates. This comprehensive study spans a period from late 2019 through early 2023, covering a wide geographic area and various population demographics to provide a detailed overview of the global impact of these co-infections.

Study Methodology and Scope

The review involved a thorough search across six major electronic databases, capturing a total of 5,095 studies, out of which 17 were deemed relevant and included for detailed analysis. The research employed the Joanna Briggs Institute Critical Appraisal Checklist to evaluate the risk of bias, and conducted meta-analysis to estimate co-infection fatality rates and relative risk. This approach allowed researchers to gather data from 38 countries or regions, offering a broad spectrum of insights.

Epidemiological Findings and Treatment Evolution

The results indicated that the prevalence of TB-COVID co-infection was found to be approximately 0.06% in West Cape Province, South Africa, and 0.02% in California, USA. Despite the global spread, treatment methodologies for TB-COVID co-infection showed little advancement since 2021. The study highlighted the severe implications of the co-infection, including increased hospitalization risks, prolonged recovery times, and higher mortality rates compared to patients infected solely with COVID-19.

Insights from the Study

Key findings from the study include:

  • The pooled fatality rate among co-infected patients was 7.1%, suggesting a slightly lower rate than previously estimated.
  • Co-infected patients in hospitals faced a mean fatality rate of 11.4%, indicating severe outcomes.
  • The relative risk of in-hospital fatality for co-infected patients compared to those with only COVID-19 was 0.8, underscoring the added risk brought by TB.

The research underscores the pressing need for ongoing study into TB-COVID co-infection, suggesting that despite a slight decline in fatality rates, these remain significantly higher than those for COVID-19 alone. This highlights the critical need for enhanced research efforts to better understand and combat the complexities of managing these co-infections.

Original Article: PLoS Negl Trop Dis. 2024 May 13;18(5):e0012136. doi: 10.1371/journal.pntd.0012136. eCollection 2024 May.

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Latest article